Dyadic Appoints Doug Pace to Its Executive Leadership Team
09 Octubre 2023 - 7:30AM
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the
“Company”) (NASDAQ: DYAI), a global biotechnology company focused
on building innovative microbial platforms to address the growing
demand for global protein bioproduction and unmet needs for
effective, affordable and accessible biopharmaceutical products and
alternative proteins for human and animal health, today announced
the appointment of Doug Pace as Executive Vice President of
Business Development. The expansion of Dyadic’s management team is
in response to the increased interest in the Company’s microbial
platforms, specifically the C1 technology for infectious disease
and other recombinant vaccines and antibodies for human and animal
pharmaceutical use, and the Dapibus™ platform for
non-pharmaceutical applications for large nutritional markets such
as dairy proteins and enzymes as well as cell culture markets for
recombinant serum albumin.
“We are pleased to welcome Doug Pace to our
leadership team as we further implement Dyadic’s corporate
development strategy. We continue to see strong interest in and
adoption of our C1 platform for pharmaceutical applications,
internal product opportunities such as recombinant albumin, and our
Dapibus™ platform for non-pharmaceutical applications, in areas
such as nutrition and health with products like recombinant casein
proteins for the dairy market. We anticipate Doug’s strong
background in specialty biopharmaceuticals will help facilitate the
expansion of our business development efforts across our core
verticals”, said Joseph Hazelton, Chief Business Officer for
Dyadic.
“The broad utility of the C1 and Dapibus™
platforms has the potential to transform biomanufacturing by
leveraging the industrial heritage of Dyadic to make affordable,
high-quality recombinant proteins and enzymes across our business
segments. I believe Dyadic is well positioned to take advantage of
the expanding preventative and therapeutic biologic markets, while
at the same time capitalizing on strategic opportunities within the
alternative proteins space. I’m extremely pleased to be able to
join Dyadic’s seasoned leadership team and have the opportunity to
be part of Dyadic’s rapid growth and bright future,” said Mr.
Pace.
Mr. Pace brings almost 30 years of
biopharmaceuticals and related experience to Dyadic in key areas of
business development, strategy, operations, and product marketing,
with biological products. He has played key roles in launching over
a dozen new products to the market. Mr. Pace spent over 3 years at
Pfizer, Inc. in their inflammation & immunology division where
he held various leadership positions in their biosimilars
portfolio. Additionally, he spent nearly 20 years at Novartis AG,
where he received awards for commercial performance with key roles
in product sales, marketing, strategy, operations, and training, in
their specialty medicines and oncology business units.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company focused on building innovative microbial
platforms to address the growing demand for global protein
bioproduction and unmet clinical needs for effective, affordable,
and accessible biopharmaceutical products and alternative proteins
for human and animal health.
Dyadic’s gene expression and protein production
platforms are based on the highly productive and scalable
fungus Thermothelomyces heterothallica (formerly
Myceliophthora thermophila). Our lead technology, C1-cell
protein production platform, is based on an industrially proven
microorganism (named C1), which is currently used to speed
development, lower production costs, and improve performance of
biologic vaccines and drugs at flexible commercial scales for the
human and animal health markets. Dyadic has also developed the
Dapibus™ filamentous fungal based microbial protein production
platform to enable the rapid development and large-scale
manufacture of low-cost proteins, metabolites, and other biologic
products for use in non-pharmaceutical applications, such as food,
nutrition, and wellness.
With a passion to enable our partners and
collaborators to develop effective preventative and therapeutic
treatments in both developed and emerging countries, Dyadic is
building an active pipeline by advancing its proprietary microbial
platform technologies, including our lead asset DYAI-100 COVID-19
vaccine candidate, as well as other biologic vaccines, antibodies,
and other biological products.
To learn more about Dyadic and our commitment to
helping bring vaccines and other biologic products to market
faster, in greater volumes and at lower cost, please
visit https://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
including those regarding Dyadic International’s expectations,
intentions, strategies, and beliefs pertaining to future events or
future financial performance, such as the success of and interest
in our protein production platforms, and the success of our
business development efforts. Actual events or results may differ
materially from those in the forward-looking statements because of
various important factors, including those described in the
Company’s most recent filings with the SEC. Dyadic assumes no
obligation to update publicly any such forward-looking statements,
whether because of new information, future events or otherwise. For
a more complete description of the risks that could cause our
actual results to differ from our current expectations, please see
the section entitled “Risk Factors” in Dyadic’s annual reports on
Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as
such factors may be updated from time to time in Dyadic’s periodic
filings with the SEC, which are accessible on the SEC’s website and
at www.dyadic.com.
Contact:Dyadic International,
Inc.Ping W. RawsonChief Financial OfficerPhone: (561)
743-8333Email: ir@dyadic.com
Dyadic (NASDAQ:DYAI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Dyadic (NASDAQ:DYAI)
Gráfica de Acción Histórica
De May 2023 a May 2024